title: Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism.
abstract: OBJECTIVE
  Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disorder. This study was to evaluate whether insulin receptor substrate (IRS)-2 Gly1057Asp polymorphism influences chronic inflammatory parameters in Taiwanese patients with PCOS.
  
  
  METHODS
  DNA was extracted from whole blood samples for genotyping and detection of IRS-2 Gly1057Asp polymorphism in 129 PCOS women and 109 control women. Ninety-seven PCOS women accepted metformin treatment for 3 months, and low-grade chronic inflammatory markers were assessed.
  
  
  RESULTS
  The levels of IL-6 were significantly elevated in PCOS women compared with normal women. Among allelic variant of IRS-2, concentrations of IL-6 were greater in IRS-2 homozygous Asp population. Treatment with metformin significantly reduced IL-6, especially in PCOS patients with IRS-2 homozygous Asp variant.
  
  
  CONCLUSIONS
  The results showed that IL-6 may be an early low-grade chronic inflammatory marker among PCOS patients with IRS-2 polymorphism in Taiwanese population. This pharmacologic study in IRS-2 polymorphism may provide more information for preventing long-term complications in PCOS.
authors.affiliation: Department of Obstetrics and Gynecology, Chi-Mei Foundation Medical Center, Tainan, Taiwan.
authors.forename: Yue-Shan
authors.initials: YS
authors.lastname: Lin
authors.forename: Shaw-Jenq
authors.initials: SJ
authors.lastname: Tsai
authors.forename: Ming-Wei
authors.initials: MW
authors.lastname: Lin
authors.forename: Cheng-Ta
authors.initials: CT
authors.lastname: Yang
authors.forename: Mei-Feng
authors.initials: MF
authors.lastname: Huang
authors.forename: Meng-Hsing
authors.initials: MH
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006720:Homozygote; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000276:immunology; D018836:Inflammation Mediators / Q000097:blood; D055504:Insulin Receptor Substrate Proteins / Q000235:genetics*; D015850:Interleukin-6 / Q000097:blood*; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology*; D011110:Polymorphism, Genetic; D013624:Taiwan / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D018836:Inflammation Mediators; D055504:Insulin Receptor Substrate Proteins; D015850:Interleukin-6; D008687:Metformin